Business Context and Reporting Period
This Form 8-K is a current report filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc.) on March 22, 2018, regarding events occurring on March 21, 2018. The Company is a Delaware corporation headquartered in Orlando, Florida, engaged in the biopharmaceutical sector.
Key Financial Metrics and Transaction Details
- Transaction Type: Sale of common stock via a Securities Purchase Agreement.
- Shares Issued: 1,250,000 shares of common stock.
- Purchase Price: $0.40 per share.
- Gross Proceeds: $500,000 (calculated as 1,250,000 shares x $0.40).
- Estimated Net Proceeds: Approximately $465,000 after deducting placement agent fees and transaction expenses.
- Placement Agent Fee: 5% of gross proceeds paid to Ascendiant Capital Markets LLC.
- Use of Proceeds: Working capital and general corporate purposes.
- Expected Closing Date: On or about March 26, 2018.
The filing does not provide specific data on revenue, profit, cash flow, margins, debt, or liquidity for the reporting period, as this is a transaction-specific report rather than a periodic financial statement.
Material Changes
The primary material change is the entry into a definitive agreement to raise capital through the issuance of new equity. This transaction represents a dilution of existing shareholders and an increase in the Company's cash position upon closing.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, earnings outlook, or management commentary regarding future operational performance. The document includes standard risk disclosures noting that representations and warranties in the Purchase Agreement are for the benefit of the parties and do not constitute statements of fact regarding the Company's actual condition. Investors are cautioned that information regarding the subject matter of these representations may change after the agreement date.
Key Facts for Investor Verification
- Verify the actual closing of the transaction on or about March 26, 2018.
- Confirm the final net proceeds received after all transaction expenses are finalized.
- Review the effective shelf registration statement (File No. 333-205228) referenced for the offering.
- Monitor subsequent filings for any changes in the Company's capital structure or use of proceeds.